RecruitingKidney Transplant RecipientsOld Age
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
Eligible age
65+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
Sponsor: Massachusetts General Hospital
You may qualify if…
- ✓ Able to give informed consent for participation in the study
- ✓ Patients who have regular outpatient follow-up at the Massachusetts General Hospital (MGH) transplant center
- ✓ ≥1 year since the latest kidney transplantation
- ✓ On IR tacrolimus as maintenance therapy
- ✓ At a stable therapeutic tacrolimus level (5-10 ng/ml) over the last ≥3 months
- ✓ Stable kidney function \[\<20% variability between the last two estimated glomerular filtration rate (eGFR)\]
- ✓ Utilizing English or Spanish as the primary language
You may not qualify if…
- ✕ Dual organ transplantation
- ✕ Rejection within the last three months
- ✕ History of moderate to severe dementia (defined by Dementia Severity Rating Scale ≥19)
- ✕ History of Parkinson's disease
- ✕ Decompensated liver disease
- ✕ Active cancer
- ✕ Uncontrolled depression or anxiety
- ✕ Blindness
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT06751992 · last updated 2026-05-28